Literature DB >> 11181370

Pharmacodynamics of daptomycin in a murine thigh model of Staphylococcus aureus infection.

A Louie1, P Kaw, W Liu, N Jumbe, M H Miller, G L Drusano.   

Abstract

Daptomycin is a lipopeptide antibiotic with activity against gram-positive bacteria, including Staphylococcus aureus. We defined the pharmacodynamic parameters that determine the activity of daptomycin for S. aureus using in vitro methods and the Craig (W. A. Craig, J. Redington, and S. C. Ebert, J. Antimicrob. Chemother. 27[Suppl. C]:29--40, 1991) neutropenic mouse thigh infection model. In Mueller-Hinton broth, the MICs for three S. aureus isolates were 0.1 to 0.2 microg/ml. In mouse serum, the MICs were 1.0 microg/ml. The protein binding of daptomycin was 90 to 92.5% in mouse serum. Single-dose intraperitoneal (i.p.) pharmacokinetic studies with infected mice showed a linear relationship between dose versus the maximum concentration of drug in serum and dose versus the area under the concentration-time curve (AUC). The serum half-life of daptomycin in infected mice was approximately 1.8 h. In single-dose, dose-ranging studies using mice, daptomycin showed a dose-response effect described by an inhibitory sigmoid E(max) (maximum effect) curve (r = 0.974; P << 0.001). The density of S. aureus in untreated controls was 8.26 log(10) CFU/g, and the E(max) was 3.97 log(10) CFU/g. The 50% effective dose (ED(50)) was 3.7 mg/kg of body weight i.p. and the stasis dose was 7.1 mg/kg. Dose fractionation studies at schedules of Q6h, Q12h, and Q24h, for total 24-h ED(30), ED(60), and ED(80) doses of 2.5, 5.6, and 15 mg/kg i.p., showed no difference in effect at each total 24-h dose level by schedule, indicating that the AUC/MIC ratio is the dynamically linked variable.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11181370      PMCID: PMC90383          DOI: 10.1128/AAC.45.3.845-851.2001

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  30 in total

1.  Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility.

Authors:  K Hiramatsu; H Hanaki; T Ino; K Yabuta; T Oguri; F C Tenover
Journal:  J Antimicrob Chemother       Date:  1997-07       Impact factor: 5.790

2.  In vitro activity of a new cyclic lipopeptide antibiotic, LY146032, against gram-positive clinical bacteria.

Authors:  P Huovinen; P Kotilainen
Journal:  Antimicrob Agents Chemother       Date:  1987-03       Impact factor: 5.191

3.  Effect of protein binding of daptomycin on MIC and antibacterial activity.

Authors:  B L Lee; M Sachdeva; H F Chambers
Journal:  Antimicrob Agents Chemother       Date:  1991-12       Impact factor: 5.191

4.  Effect of 2',3'-didehydro-3'-deoxythymidine in an in vitro hollow-fiber pharmacodynamic model system correlates with results of dose-ranging clinical studies.

Authors:  J A Bilello; G Bauer; M N Dudley; G A Cole; G L Drusano
Journal:  Antimicrob Agents Chemother       Date:  1994-06       Impact factor: 5.191

5.  Role for dual individualization with cefmenoxime.

Authors:  J J Schentag; I L Smith; D J Swanson; C DeAngelis; J E Fracasso; A Vari; J W Vance
Journal:  Am J Med       Date:  1984-12-21       Impact factor: 4.965

6.  Pharmacodynamics of a fluoroquinolone antimicrobial agent in a neutropenic rat model of Pseudomonas sepsis.

Authors:  G L Drusano; D E Johnson; M Rosen; H C Standiford
Journal:  Antimicrob Agents Chemother       Date:  1993-03       Impact factor: 5.191

7.  Constant infusions vs. intermittent doses of gentamicin against Pseudomonas aeruginosa in vitro.

Authors:  A U Gerber; P Wiprächtiger; U Stettler-Spichiger; G Lebek
Journal:  J Infect Dis       Date:  1982-04       Impact factor: 5.226

8.  Single-dose pharmacokinetics and antibacterial activity of daptomycin, a new lipopeptide antibiotic, in healthy volunteers.

Authors:  J R Woodworth; E H Nyhart; G L Brier; J D Wolny; H R Black
Journal:  Antimicrob Agents Chemother       Date:  1992-02       Impact factor: 5.191

9.  Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients.

Authors:  A Forrest; D E Nix; C H Ballow; T F Goss; M C Birmingham; J J Schentag
Journal:  Antimicrob Agents Chemother       Date:  1993-05       Impact factor: 5.191

10.  Bactericidal activity of vancomycin, daptomycin, ampicillin and aminoglycosides against vancomycin-resistant Enterococcus faecium.

Authors:  E Bingen; N Lambert-Zechovsky; R Leclercq; C Doit; P Mariani-Kurkdjian
Journal:  J Antimicrob Chemother       Date:  1990-11       Impact factor: 5.790

View more
  55 in total

1.  Population pharmacokinetics of daptomycin.

Authors:  Barry Dvorchik; Robert D Arbeit; Julia Chung; Susan Liu; William Knebel; Helen Kastrissios
Journal:  Antimicrob Agents Chemother       Date:  2004-08       Impact factor: 5.191

2.  Pharmacodynamic functions: a multiparameter approach to the design of antibiotic treatment regimens.

Authors:  Roland R Regoes; Camilla Wiuff; Renata M Zappala; Kim N Garner; Fernando Baquero; Bruce R Levin
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

3.  Dosing ethambutol in obese patients.

Authors:  Jan-Willem Alffenaar; Tjip van der Werf
Journal:  Antimicrob Agents Chemother       Date:  2010-09       Impact factor: 5.191

4.  Efficacy of novel rifamycin derivatives against rifamycin-sensitive and -resistant Staphylococcus aureus isolates in murine models of infection.

Authors:  David M Rothstein; Ronald S Farquhar; Klari Sirokman; Karen L Sondergaard; Charles Hazlett; Angelia A Doye; Judith K Gwathmey; Steve Mullin; John van Duzer; Christopher K Murphy
Journal:  Antimicrob Agents Chemother       Date:  2006-08-28       Impact factor: 5.191

5.  Pharmacodynamic model to describe the concentration-dependent selection of cefotaxime-resistant Escherichia coli.

Authors:  Sara K Olofsson; Patricia Geli; Dan I Andersson; Otto Cars
Journal:  Antimicrob Agents Chemother       Date:  2005-12       Impact factor: 5.191

6.  Short-course gentamicin in combination with daptomycin or vancomycin against Staphylococcus aureus in an in vitro pharmacodynamic model with simulated endocardial vegetations.

Authors:  Brian T Tsuji; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2005-07       Impact factor: 5.191

7.  Modeling the mechanism of postantibiotic effect and determining implications for dosing regimens.

Authors:  Patricia Geli
Journal:  J Math Biol       Date:  2009-02-03       Impact factor: 2.259

Review 8.  Protein binding of antimicrobials: methods for quantification and for investigation of its impact on bacterial killing.

Authors:  Jürgen Beer; Claudia Christina Wagner; Markus Zeitlinger
Journal:  AAPS J       Date:  2009-01-01       Impact factor: 4.009

9.  Relationship between susceptibility to daptomycin in vitro and activity in vivo in a rabbit model of aortic valve endocarditis.

Authors:  H F Chambers; L Basuino; B A Diep; J Steenbergen; S Zhang; P Tattevin; J Alder
Journal:  Antimicrob Agents Chemother       Date:  2009-01-26       Impact factor: 5.191

10.  Single-dose daptomycin pharmacokinetics in chronic haemodialysis patients.

Authors:  Noha N Salama; Jonathan H Segal; Mariann D Churchwell; Jignesh H Patel; Lihong Gao; Michael Heung; Bruce A Mueller
Journal:  Nephrol Dial Transplant       Date:  2009-12-10       Impact factor: 5.992

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.